A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia

Trial Profile

A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Fibromyalgia; Iron deficiency anaemia
  • Focus Therapeutic Use
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 17 Nov 2015 Planned End Date changed from 1 Sep 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 17 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top